Adam Crystal Sells 20,251 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 20,251 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $15.00, for a total transaction of $303,765.00. Following the transaction, the insider owned 112,622 shares in the company, valued at approximately $1,689,330. This represents a 15.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Adam Crystal also recently made the following trade(s):

• On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.77, for a total transaction of $693,985.65.
• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.26, for a total value of $226,221.52.

Tango Therapeutics Price Performance

NASDAQ TNGX traded down $0.50 during midday trading on Monday, hitting $16.45. 3,491,389 shares of the company traded hands, compared to its average volume of 3,462,552. Tango Therapeutics, Inc. has a 52 week low of $1.03 and a 52 week high of $17.63. The company’s 50-day simple moving average is $11.86 and its 200-day simple moving average is $9.48. The company has a market cap of $2.35 billion, a PE ratio of -18.91 and a beta of 1.76.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. On average, research analysts predict that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Wall Street Analyst Weigh In

TNGX has been the topic of a number of recent analyst reports. Mizuho began coverage on shares of Tango Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $19.00 price target on the stock. B. Riley Financial increased their target price on shares of Tango Therapeutics from $8.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Piper Sandler raised their target price on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. HC Wainwright upped their price target on Tango Therapeutics from $13.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Wall Street Zen lowered Tango Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.38.

Institutional Trading of Tango Therapeutics

Several large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC increased its stake in Tango Therapeutics by 21.4% during the 4th quarter. Farallon Capital Management LLC now owns 13,061,411 shares of the company’s stock valued at $115,724,000 after purchasing an additional 2,304,411 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Tango Therapeutics by 322.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company’s stock worth $93,986,000 after buying an additional 8,096,924 shares during the period. Siren L.L.C. grew its holdings in shares of Tango Therapeutics by 38.8% during the fourth quarter. Siren L.L.C. now owns 8,165,374 shares of the company’s stock valued at $72,345,000 after buying an additional 2,282,186 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Tango Therapeutics by 33.6% in the 4th quarter. Vanguard Group Inc. now owns 6,750,977 shares of the company’s stock valued at $59,814,000 after acquiring an additional 1,698,974 shares during the period. Finally, State Street Corp increased its position in shares of Tango Therapeutics by 84.8% in the 4th quarter. State Street Corp now owns 6,218,567 shares of the company’s stock valued at $55,097,000 after acquiring an additional 2,853,362 shares during the period. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.